G1M1 + G7M8

G1M1 and G7M8 are novel minibodies (Mbs) derived from camelid nanobodies (Nbs) fused to a human IgG1 Fc fragment, designed to specifically inhibit Galectin-1 (GAL-1) and Galectin-7 (GAL-7), respectively. These galectins are glyco-immune checkpoints overexpressed in approximately 40% of triple-negative breast cancer (TNBC) cases, where they contribute to immunosuppression, metastatic dissemination, and treatment resistance. By blocking the binding of GAL-1 and GAL-7 to T-cell glycoreceptors, these inhibitors prevent T-cell apoptosis and modulate both local and systemic immune responses. Preclinical studies in TNBC mouse models have demonstrated that these inhibitors, used as monotherapies or in combination, can reduce lung metastases and show therapeutic potential comparable to anti-PD-1 immunotherapy. Additionally, the parent nanobodies have been utilized as radiotracers for PET imaging to detect galectin expression in tumors.

Other names

galectin-1 inhibitor + galectin-7 inhibitorGAL-1 inhibitor + GAL-7 inhibitor